EphA2 receptor tyrosine kinase (RTK) is a cell-surface protein that is overexpressed and implicated in the progression of many solid cancers, including NSCLC, making it a promising target for anti-cancer therapy [5,6,7,8]. The gene discussed is EPHA2; the disease is non-small cell lung carcinoma.